WeLeader Biomedical Co

WeLeader Biomedical Co Financial Leverage

The Financial Leverage (Equity Multiplier) of WeLeader Biomedical Co (7713.TWO) as of Oct 16, 2026 is 1.94. In the previous year, Financial Leverage (Equity Multiplier) was 2.20 — a change of -11.64% (lower).

Financial Leverage

1.94

YoY

-11.64%

Last updated:

Financial Leverage (Equity Multiplier) of WeLeader Biomedical Co is 2025 1.94 . Financial Leverage (Equity Multiplier) of WeLeader Biomedical Co was 2024 2.20 . It decreases by -11.64% lower compared to the previous year.

The WeLeader Biomedical Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2020
3.27 TWD
Jan 1, 2021
2.47 TWD
Jan 1, 2022
2.48 TWD
Jan 1, 2023
2.04 TWD
Jan 1, 2024
2.20 TWD
Jan 1, 2025
1.94 TWD
The WeLeader Biomedical Co Financial Leverage history
YEARFinancial LeverageYoY
1.94-11.64%
2.20+7.68%
2.04-17.52%
2.48+0.23%
2.47-24.44%
3.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd is a Taiwan-based company operating in the Health Care sector, specifically within Health Care Providers & Services. Headquartered in Kaohsiung, the company focuses on the agency and trading of in vitro diagnostic instruments and reagent-related products. It provides medical testing-related services, including distribution, after-sales, and maintenance for laboratory reagents, consumables, instruments, and equipment. Additionally, the company offers construction planning for medical testing laboratories, equipment procurement, operational coaching, and ancillary services such as human resources development and training. WeLeader Biomedical also develops digital medical examination platforms. The firm primarily serves the domestic market, with its products and services mainly sold within Taiwan. The company completed its initial public offering (IPO) on January 2, 2024, and is listed under the ticker symbol 7713.TWO with ISIN TW0007713000. Its website is https://www.weleader.com.tw/. The company operates in the health care industry, emphasizing diagnostic solutions and laboratory support services within Taiwan's medical infrastructure. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WeLeader Biomedical Co stock

Financial Leverage (Equity Multiplier) of WeLeader Biomedical Co is 1.94 in 2025.

Financial Leverage (Equity Multiplier) of WeLeader Biomedical Co changed from 2.20 to 1.94, representing a -11.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s WeLeader Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — WeLeader Biomedical Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — WeLeader Biomedical Co